NCT01532115

Effect of BIA 9-1067 on Cardiac Repolarization in Healthy Adult Men and Women

A Randomized, Double-blind, Placebo-controlled and Open-label Active-controlled, 4-period Crossover Trial to Evaluate the Effect of BIA 9-1067 on Cardiac Repolarization in Healthy Adult Men and Women

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 64 (actual)
• Sponsor: Bial - Portela C S.A. · Industry
• Sex: All
• Age: 18 Years – 55 Years
• Healthy volunteers: Accepted

Summary

The purpose of this study is to evaluate the effect of BIA 9-1067 on the cardiac repolarization in adult healthy men and women volunteers.

Detailed description

Single-centre, randomized, double-blind, placebo-controlled and open-label active-controlled, 4-period crossover trial in healthy male and female subjects

Conditions

• Parkinson Disease

Interventions

Type	Name	Description
DRUG	BIA 9-1067	50 mg and 800 mg of BIA 9-1067 (single-dose)
DRUG	Placebo	single-dose
DRUG	moxifloxacin	400 mg moxifloxacin (single-dose)

Timeline

• Start date: 2010-05-01
• Primary completion: 2010-10-01
• Completion: 2011-05-01
• First posted: 2012-02-14
• Last updated: 2012-06-21

Locations

1 site across 1 country: France